medigraphic.com
Anales de Otorrinolaringología Mexicana

2021, Number 1

<< Back Next >>

Otorrinolaringología 2021; 66 (1)

Management of epistaxis in COVID-19 patients

Gasós-Lafuente AM, Lavilla-Martín de Valmaseda MJ, Navarro-Mediano A, Martínez-Ruiz Coello M, Plaza-Mayor G, García-Purriños F, Mateos-Serrano B, Campos-González A, Villacampa-Aubá JM, Estévez-Alonso S, Del Rey Tomás-Biosca FJ, Lois-Ortega Y, Úbeda FE, Martin-Villares C, Morales-Angulo C

Language: Spanish
References: 27
Page: 43-51
PDF size: 237.48 Kb.


ABSTRACT

Background: The use of anticoagulants and high-flow oxygen therapy are therapies that may predispose to epistaxis. Both factors often coexist in patients affected by SARSCoV- 2, which caused the recent global pandemic of COVID-19.
Objective: To investigate the clinical-epidemiological characteristics of patients with COVID-19 who develop epistaxis, as well as its triggers and management, among others.
Materials and Methods: A multicenter, retrospective, descriptive study in COVID- 19 patients with a positive PCR test who presented epistaxis throughout the disease. Study was done from January 31st May 19th, 2020. Demographic data were collected on previous comorbidities, treatments, complications related to COVID-19, triggers, severity of epistaxis, treatment indicated and evolution, among others.
Results: A total of 18 patients between the ages of 54 and 88 were included, and 72% were male. They were attended in 9 different hospitals throughout Spain, presenting between 1 to 3 cases each. In 83.3% of the patients epistaxis had some specific trigger, being multiple in 16.6% of them. However, nasopharyngeal smear taken for PCR was not the cause in any case. The most frequent type of treatment was an anterior nasal packing.
Conclusions: Although patients with COVID-19 constitute a special risk group for epistaxis given their associated comorbidities, severe epistaxis is rare in this group of patients. The management of these patients is also complex due to the working conditions when assisting these patients and should always keep healthcare workers safe.


REFERENCES

  1. Chen N, Zhou M, Dong X, Qu J , et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-13. doi.10.1016/S0140- 6736(20)30211-7.

  2. Rothe C, Schunk M, Sothmann P, Bretzel G, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382 (10): 970-1. doi. 10.1056/NEJMc2001468.

  3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020;10.1001/jama.2020.12839. doi. 10.1001/ jama.2020.12839.

  4. Li Q, Guan X, Wu P, Wang X, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382 (13): 1199-1207. doi. 10.1056/NEJMoa2001316.

  5. Wang W, Xu Y, Gao R, Lu R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323 (18): 1843-4. doi. 10.1001/jama.2020.3786.

  6. Røsjø H, Varpula M, Hagve TA, Karlsson S, et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med 2011; 37 (1): 77-85. doi.10.1007/ s00134-010-2051-x.

  7. Pallin DJ, Chng YM, McKay MP, Emond JA, et al. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med 2005; 46 (1): 77-81. doi. 10.1016/j. annemergmed.2004.12.014.

  8. Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg 2006; 64 (3): 511-8. doi. 10.1016/j.joms.2005.11.031.

  9. Choudhury N, Sharp HR, Mir N, Salama NY. Epistaxis and oral anticoagulant therapy. Rhinology 2004; 42 (2): 92-7.

  10. Upile T, Jerjes W, Sipaul F, El Maaytah M, et al. A change in UK epistaxis management. Eur Arch Otorhinolaryngol 2008; 265 (11): 1349-54. doi. 10.1007/s00405-008-0657-1.

  11. Bergler W, Sadick H, Gotte K, Riedel F, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111 (3 Pt 1): 222-8. doi. 10.1177/000348940211100306.

  12. Saraceni-Neto P, Nunes LM, Gregório LC, Santos R de P, et al. Surgical treatment of severe epistaxis: an eleven-year experience. Braz J Otorhinolaryngol 2013; 79 (1): 59-64. doi. 10.5935/1808-8694.20130011.

  13. Gomes P, Salvador P, Lombo C, Caselhos S, et al. Role of age and anticoagulants in recurrent idiopathic epistaxis. Acta Otorrinolaringol Esp 2020; 71 (3): 160-5. doi. 10.1016/j. otorri.2019.05.003.

  14. Abrich V, Brozek A, Boyle TR, Chyou PH, et al. Risk factors for recurrent spontaneous epistaxis. Mayo Clin Proc 2014; 89 (12): 1636-43. doi. 10.1016/j.mayocp.2014.09.009.

  15. Wölfel R, Corman VM, Guggemos W, Seilmaier M, et al. Virological assessment of hospitalized patients with COVID- 2019. Nature 2020; 581 (7809): 465-9. doi. 10.1038/ s41586-020-2196-x.

  16. Thamboo A, Lea J, Sommer DD, Sowerby L, et al. Clinical evidence-based review and recommendations of aerosol generating medical procedures in otolaryngology - head and neck surgery during the COVID-19 pandemic. J Otolaryngol Head Neck Surg 2020; 49 (1): 28. doi. 10.1186/ s40463-020-00425-6.

  17. Cui C, Yao Q, Zhang D, Zhao Y, et al. Approaching otolaryngology patients during the COVID-19 pandemic. Otolaryngol Head Neck Surg 2020; 163 (1): 121-31. doi. 10.1177/0194599820926144.

  18. D’Aguanno V, Ralli M, Greco A, de Vincentiis M. Clinical recommendations for epistaxis management during the COVID-19 pandemic. Otolaryngol Head Neck Surg 2020; 163 (1): 75-7. doi. 10.1177/0194599820926497.

  19. Recomendaciones de la seorl-ccc para la práctica de la especialidad durante la pandemia de covid-19 (22 de marzo de 2020). https://seorl.net/wp-content/uploads/2020/03/ Recomendaciones-de-la-SEORL-CCC-22-de-marzode- 2020.pdf).

  20. Nham E, Ko JH, Jeong BH, Huh K, et al. Severe thrombocytopenia in a patient with COVID-19. Infect Chemother 2020; 23.

  21. Baldacini M, Pop R, Sattler L, Mauvieux L, et al. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia. Br J Haematol 2020; 189 (6): 1054-6. doi. 10.1111/bjh.16768.

  22. LoSavio PS, Patel T, Urban MJ, Tajudeen B, et al. Management of upper airway bleeding in COVID-19 patients on extracorporeal membrane oxygenation. Laryngoscope 2020; 10.1002/lary.28846. doi. 10.1002/lary.28846.

  23. Dell’Era V, Dosdegani R, Valletti PA, Garzaro M. Epistaxis in hospitalized patients with COVID-19. Int Med Res 2020; 48: 300060520951040. doi. 10.1177/0300060520951040.

  24. Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol 2014; 5: 649. doi. 10.3389/fimmu.2014.00649.

  25. Cao B, Wang Y, Wen D, Liu W, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 (19): 1787-99. doi. 10.1056/NEJMoa2001282.

  26. Bathula SSR, Patrick T, Srikantha L. Epistaxis management on COVID-19-positive patients: our early case experience and treatment. Clin Case Rep 2020; 21. doi. 10.1002/ ccr3.3137.

  27. Hussain MH, Mair M, Rea PJ. Epistaxis as a marker for severe acute respiratory syndrome coronavirus-2 status - a prospective study. Laryngol Otol 2020; 134 (8): 717-720. doi. 10.1017/S0022215120001863.




2020     |     www.medigraphic.com